Effect of silica-based mesoporous nanomaterials on human blood cells
Copyright © 2023 Elsevier B.V. All rights reserved..
Different mesoporous nanomaterials (MSNs) are constantly being developed for a range of therapeutic purposes, but they invariably interact with blood components and may cause hazardous side effects. Therefore, when designing and developing nanoparticles for biomedical applications, hemocompatibility should be one of the primary goals to assess their toxicity at the cellular level of all blood components. The aim of this study was to evaluate the compatibility of human blood cells (erythrocytes, platelets, and leukocytes) after exposure to silica-based mesoporous nanomaterials that had been manufactured using the sol-gel method, with Ca and Ce as doping elements. The viability of lymphocytes and monocytes was unaffected by the presence of MSNs at any concentration. However, it was found that all nanomaterials, at all concentrations, reduced the viability of granulocytes. P-selectin expression of all MSNs at all concentrations was statistically significantly higher in platelet incubation on the first day of storage (day 1) compared to the control. When incubated with MSNs, preserved platelets displayed higher levels of iROS at all MSNs types and concentrations examined. Ce-containing MSNs presented a slightly better hemocompatibility, although it was also dose dependent. Further research is required to determine how the unique characteristics of MSNs may affect various blood components in order to design safe and effective MSNs for various biomedical applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:387 |
|---|---|
| Enthalten in: |
Chemico-biological interactions - 387(2023) vom: 05. Jan., Seite 110784 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fortis, Sotirios P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7631-86-9 |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cbi.2023.110784 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364316349 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364316349 | ||
| 003 | DE-627 | ||
| 005 | 20231227140922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cbi.2023.110784 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM364316349 | ||
| 035 | |a (NLM)37939894 | ||
| 035 | |a (PII)S0009-2797(23)00451-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fortis, Sotirios P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of silica-based mesoporous nanomaterials on human blood cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Different mesoporous nanomaterials (MSNs) are constantly being developed for a range of therapeutic purposes, but they invariably interact with blood components and may cause hazardous side effects. Therefore, when designing and developing nanoparticles for biomedical applications, hemocompatibility should be one of the primary goals to assess their toxicity at the cellular level of all blood components. The aim of this study was to evaluate the compatibility of human blood cells (erythrocytes, platelets, and leukocytes) after exposure to silica-based mesoporous nanomaterials that had been manufactured using the sol-gel method, with Ca and Ce as doping elements. The viability of lymphocytes and monocytes was unaffected by the presence of MSNs at any concentration. However, it was found that all nanomaterials, at all concentrations, reduced the viability of granulocytes. P-selectin expression of all MSNs at all concentrations was statistically significantly higher in platelet incubation on the first day of storage (day 1) compared to the control. When incubated with MSNs, preserved platelets displayed higher levels of iROS at all MSNs types and concentrations examined. Ce-containing MSNs presented a slightly better hemocompatibility, although it was also dose dependent. Further research is required to determine how the unique characteristics of MSNs may affect various blood components in order to design safe and effective MSNs for various biomedical applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Calcium ions | |
| 650 | 4 | |a Cerium ions | |
| 650 | 4 | |a Cytotoxicity | |
| 650 | 4 | |a Mesoporous silica nanomaterials | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a White blood cells | |
| 650 | 4 | |a platelets | |
| 650 | 7 | |a Silicon Dioxide |2 NLM | |
| 650 | 7 | |a 7631-86-9 |2 NLM | |
| 700 | 1 | |a Batrinou, Anthimia |e verfasserin |4 aut | |
| 700 | 1 | |a Georgatzakou, Hara T |e verfasserin |4 aut | |
| 700 | 1 | |a Tsamesidis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Alvanidis, Grigorios |e verfasserin |4 aut | |
| 700 | 1 | |a Papageorgiou, Effie G |e verfasserin |4 aut | |
| 700 | 1 | |a Stamoulis, Kontantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Gkiliopoulos, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Pouroutzidou, Georgia K |e verfasserin |4 aut | |
| 700 | 1 | |a Theocharidou, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Kontonasaki, Eleana |e verfasserin |4 aut | |
| 700 | 1 | |a Kriebardis, Anastasios G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemico-biological interactions |d 1969 |g 387(2023) vom: 05. Jan., Seite 110784 |w (DE-627)NLM000001848 |x 1872-7786 |7 nnns |
| 773 | 1 | 8 | |g volume:387 |g year:2023 |g day:05 |g month:01 |g pages:110784 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cbi.2023.110784 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 387 |j 2023 |b 05 |c 01 |h 110784 | ||